Dr. Jonathan M. Fenkel, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 319
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Jefferson Medical College of Thomas Jefferson University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
PA license MD443298 · NJ license 25MA08540400
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Thomas Jefferson University Hospital Philadelphia, PA
- Jefferson Stratford Hospital Stratford, NJ
Medical groups
- Jefferson University Physicians (1,531 clinicians)
- Jefferson University Physicians of New Jersey PC (119 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 319
- Services billed
- 585
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 260 | 210 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 91 | 34 |
| Established patient office or other outpatient visit, 20-29 minutes | 73 | 68 |
| Established patient office or other outpatient visit, 40-54 minutes | 37 | 33 |
| New patient office or other outpatient visit, 45-59 minutes | 37 | 37 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 26 | 15 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 25 | 24 |
| Measurement of liver stiffness | 20 | 20 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | 11 |
| Biopsy of large bowel using a flexible endoscope | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xifaxan (rifaximin) Other prescribers in Philadelphia, PA | 287 |
| Ursodiol Other prescribers in Philadelphia, PA | 212 |
| Vemlidy (tenofovir alafenamide) | 181 |
| Tacrolimus Other prescribers in Philadelphia, PA | 178 |
| Pantoprazole Sodium Other prescribers in Philadelphia, PA | 120 |
| Spironolactone Other prescribers in Philadelphia, PA | 91 |
| Furosemide Other prescribers in Philadelphia, PA | 80 |
| Entecavir | 80 |
| Lactulose Other prescribers in Philadelphia, PA | 69 |
| Gabapentin Other prescribers in Philadelphia, PA | 61 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $7,821 in total to this clinician.
| Ipsen Biopharmaceuticals, Inc | $5,585 |
|---|---|
| Gilead Sciences, Inc. | $2,205 |
| Alnylam Pharmaceuticals Inc. | $30.95 |
| Compensation for services other than consulting (speaking, faculty) | $5,000 |
|---|---|
| Consulting Fee | $2,040 |
| Food and Beverage | $396 |
| Travel and Lodging | $386 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,000 |
| Gilead Sciences, Inc. Nov 18, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4243091;VEM US;10588904 | $2,040 |
| Ipsen Biopharmaceuticals, Inc Jun 13, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Washington dc, DC · in-kind | $386 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $25,475 in research payments for these studies, mostly to the institutions running them.
- M20-350 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE) Pibrenta…
AbbVie Inc. - A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
Ipsen Bioscience Inc. · Active, not recruiting · NCT05627362 - Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
AbbVie Inc. · Completed · NCT04903626 - An Observational Disease and Clinical Outcomes Registry of Patients with Lysosomal Acid Lipase (LAL) Deficiency
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.